ICON

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICON (ICLR) reports robust earnings, eyes strategic partnerships for growth

ICON's Q4 2022 earnings reflect strong financial performance and strategic advancements. While facing challenges in pricing and COVID-related headwinds, the company is well-positioned to capitalize on growth opportunities through margin maintenance, strategic partnerships, and M&A focus.

ICON (ICLR) reports stable Q1 earnings, eyes growth amid challenges

ICON's Q1 2023 earnings call highlighted solid financial performance, strategic partnerships, and investments in innovation. While facing challenges in pricing negotiations and biotech funding, the company remains resilient and focused on growth opportunities. Stabilizing backlog burn rates, leveraging innovative tools, and addressing labor market dynamics present avenues for future success.

ICON reports solid Q2 performance and eyes growth opportunities

ICON's Q2 performance reflects growth momentum and strong financial outlook for 2023. Challenges include growth uncertainty and revenue predictability amid customer fluctuations. Opportunities lie in strategic partnerships, margin improvement, and market expansion.

ICON (ICLR) posts robust Q3 results, eyes growth amid challenges

ICON (ICLR) reports strong Q3 earnings, emphasizing revenue growth, strategic partnerships, and operational improvements. The company faces challenges from macroeconomic factors and customer concentration but sees opportunities in RFP growth and R&D budget expansion. With a focus on innovation and adaptability, ICON aims to maintain its strong performance and capitalize on future opportunities.

ICON (ICLR) reports strong Q4 earnings, eyes strategic growth

ICON's strong performance in Q4 and 2023 driven by revenue growth and margin improvement
Challenges include customer concerns over R&D spend and wide revenue guidance range for 2024
Opportunities lie in new partnerships, automation for margin expansion, and capital deployment priorities
Overall, ICON remains competitive, with positive outlook for future growth and development

ICON (ICLR) reports strong Q1 earnings and strategic growth outlook

ICON (ICLR) delivered a strong performance in Q1 2024, with robust financial results, strategic initiatives, and updated guidance reflecting confidence in future prospects.
While facing challenges such as revenue fluctuations and analyst inquiries, the company's strengths in client engagement, operational efficiency, and market positioning provide a solid foundation for growth.
Opportunities in M&A, customer base diversification, and data strategy underscore potential avenues for expansion and innovation, positioning ICON well for continued success in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--ICON Announces CFO Transition.

ICON Announces CFO Transition

If you are looking for stocks that are well positioned to maintain their recent uptrend, Icon PLC (ICLR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in Icon PLC (ICLR) is Your Friend, Here's Why

DUBLIN--(BUSINESS WIRE)--ICON plc Schedules First Quarter 2024 Earnings Conference Call.

ICON plc Schedules First Quarter 2024 Earnings Conference Call

ICON (ICLR) reported earnings 30 days ago. What's next for the stock?

ICON (ICLR) Up 7.6% Since Last Earnings Report: Can It Continue?

Icon PLC (ICLR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Icon PLC (ICLR) Is a Great Choice for 'Trend' Investors, Here's Why

Doximity

Investors with an interest in Medical Services stocks have likely encountered both Icon PLC (ICLR) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?

ICLR vs. DOCS: Which Stock Is the Better Value Option?

Cencora Inc

Elevance Health Inc

The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and ICLR are set to gain the most.

3 Medical Services Stocks to Buy as Industry Trends Improve

ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.

ICON (ICLR) Gains From Strategic Deals, New Innovations

Does Icon PLC (ICLR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Icon PLC (ICLR) is a Great Choice

Icon PLC (ICLR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Icon PLC (ICLR) Rating Upgrade to Buy

Here's Why Momentum in Icon PLC (ICLR) Should Keep going

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at Upcoming Investor Conferences.

ICON plc to Present at Upcoming Investor Conferences

ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.

ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand

ICON Public Limited Company (ICLR) Q4 2023 Earnings Call Transcript

Icon PLC (ICLR) came out with quarterly earnings of $3.46 per share, beating the Zacks Consensus Estimate of $3.44 per share. This compares to earnings of $3.13 per share a year ago.

Icon PLC (ICLR) Q4 Earnings Surpass Estimates

DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2023 Results.

ICON Reports Fourth Quarter and Full Year 2023 Results

ICON Public is a global clinical research organization that provides services for the pharmaceutical, biotechnology, and medical device industries. The clinical research organization sector is expected to have strong growth due to increased drug research and development, providing opportunities for ICON's growth. The company has been 'digesting' a huge 2021 merger that loaded it with debt and diluted outstanding shares.

ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?

DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call.

ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference

The market's response after ICON's Q3 numbers indicates it is forecasting a period of better business for the company in 2024. ICLR's projected earnings growth out to 2025 is 9-14% on sales growth of 5-7%. Despite a strong company, current multiples are expensive, increasing starting valuations and reducing short-term return potential.

ICON: Starting Valuations And Business Returns Are 2 Major Hurdles

Icon PLC (ICLR) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Icon PLC (ICLR)

Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Doximity (DOCS). But which of these two stocks offers value investors a better bang for their buck right now?

ICLR or DOCS: Which Is the Better Value Stock Right Now?

Confluent

ImmunoGen

Pinterest

Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.

4 Stocks to Invest in for Remarkable Earnings Acceleration

Icon PLC (ICLR) possesses solid growth attributes, which could help it handily outperform the market.

Here is Why Growth Investors Should Buy Icon PLC (ICLR) Now

ICON Public Limited Company (NASDAQ:ICLR ) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET Company Participants Kate Haven - VP, IR Steven Cutler - CEO & Director Brendan Brennan - CFO Conference Call Participants Eric Coldwell - Baird Justin Bowers - Deutsche Bank Derik De Bruin - Bank of America Elizabeth Anderson - Evercore ISI Jack Meehan - Nephron Research Patrick Donnelly - Citi Casey Woodring - JPMorgan David Windley - Jefferies Tim Dale - Wells Fargo Jack Wallace - Guggenheim Partners Ann Hynes - Mizuho Securities Kate Haven Good day, and thank you for joining us on this call covering the quarter ended September 30, 2023. Also on the call today, we have our CEO, Dr. Steve Cutler; and our CFO, Mr.

News for ICON Stock (ICLR)